Posted by Michael Wonder on 27 May 2023
Highlights from the CHMP 22-25 May 2023 meeting
26 May 2023 - The EMA’s CHMP recommended two medicines for approval at its May 2023 meeting.
The committee recommended granting a marketing authorisation for Pylclari (piflufolastat (18F)), intended for the diagnosis of prostate cancer.
